For the Inventor, By the Inventor

Enter assignee name

Palo Alto, CA, United States of America

Telik, Inc.

USPTO Granted Patents = 37

% Expired Patents = 75.7

CIPO Patents = 1

EPO Patents = 3

Forward Citations = 132

Loading Chart...

Loading Chart...

78 inventors (with patents filed for the assignee):

Steven R Schow (15 out of 29 patents)

Hugo O Villar (12 out of 21 patents)

Louise Robinson (11 out of 14 patents)

4. Robert T Lum (9 out of 25 patents)

5. Edgardo Laborde (7 out of 14 patents)

6. Wayne R Spevak (6 out of 12 patents)

7. Michael R Kozlowski (6 out of 15 patents)

8. Songyuan Shi (5 out of 35 patents)

9. Lawrence M Kauvar (5 out of 84 patents)

10. Wenli Ma (5 out of 5 patents)

11. Fanying Meng (5 out of 9 patents)

12. Brian T Peterson (5 out of 8 patents)

13. Yukiharu Matsumoto (5 out of 14 patents)

14. Prasad V V S V Manchem (5 out of 5 patents)

15. Kouji Matsushima (4 out of 39 patents)

37 patents: Sort by Forward Citations

1. 8841476 - Preparation of crystalline ezatiostat hydrochloride ansolvate form D (2014-09-23),

2. 8759303 - Compositions and methods for treating myelodysplastic syndrome (2014-06-24),

3. 8716521 - Formulations of canfosfamide and their preparation (2014-05-06),

4. 8481781 - Formulations of canfosfamide and their preparation (2013-07-09),

5. 8410163 - Substituted 4-amino-5-benzoyl-2-(phenylamino)thiophene-3-carbonitriles and substituted 4-amino-5-benzoyl-2-(phenylamino)thiophene-3-carboxamides as tubulin polymerization inhibitors (2013-04-02),

6. 8361971 - Tablet formulation of ezatiostat (2013-01-29),

7. 8334266 - Process for and intermediates in the preparation of canfosfamide and its salts (2012-12-18),

8. 8324426 - Formulations of canfosfamide and their preparation (2012-12-04),

9. 8207121 - Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound (2012-06-26),

10. 8198247 - Process for and intermediates in the preparation of canfosfamide and its salts (2012-06-12),

11. 8129396 - 2-[1H-benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors (2012-03-06),

12. 8093231 - Sulfonylethyl phosphorodiamidates (2012-01-10),

13. 7872134 - 2-{[2-(substituted amino)ethyl]sulfonyl}ethyl N,N-bis(2-chloroethyl)phosphorodiamidates (2011-01-18),

14. 7655799 - 2{[2-(substituted amino)ethyl]sulfonyl}ethyl N,N,N',N'-tetrakis(2-chloroethyl)phosphorodiamidates (2010-02-02),

15. 7297696 - Antagonists of MCP-1 function and methods of use thereof (2007-11-20),

Telik, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative small molecule drugs to treat cancer and other serious diseases. With a dedicated team of scientists and researchers, Telik is committed to advancing medical science and delivering impactful therapies to patients in need.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

37 Patents

#53 in Palo Alto, CA

#2,183 in California

#9,231 in US

#18,212 in the World

Palo Alto, CA, United States of America

Telik, Inc.

Forward Citations = 132

78 inventors:

Steven R Schow (15 out of 29 patents)

Hugo O Villar (12 out of 21 patents)

Louise Robinson (11 out of 14 patents)

4. Robert T Lum (9 out of 25 patents)

5. Edgardo Laborde (7 out of 14 patents)

Please report any incorrect information to [email protected]

Loading…